• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis.

作者信息

Gong Cynthia L, Studdert Ann L, Liedtke Michaela

机构信息

Stanford Center for High Value Care, Stanford, California.

Stanford Cancer Institute, Stanford University Medical Center, Stanford, California.

出版信息

Am J Hematol. 2019 Mar;94(3):E68-E70. doi: 10.1002/ajh.25372. Epub 2018 Dec 18.

DOI:10.1002/ajh.25372
PMID:30536952
Abstract
摘要

相似文献

1
Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis.达雷妥尤单抗与泊马度胺治疗复发/难治性多发性骨髓瘤的成本效益分析。
Am J Hematol. 2019 Mar;94(3):E68-E70. doi: 10.1002/ajh.25372. Epub 2018 Dec 18.
2
Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.泊马度胺、卡非佐米和达雷妥尤单抗用于治疗美国多次接受治疗的复发难治性多发性骨髓瘤患者的成本效益
Clin Ther. 2017 Oct;39(10):1986-2005.e5. doi: 10.1016/j.clinthera.2017.08.010. Epub 2017 Sep 28.
3
Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.泊马度胺在瑞典复发难治性多发性骨髓瘤患者中的成本效益
Acta Oncol. 2016 May;55(5):554-60. doi: 10.3109/0284186X.2015.1096021. Epub 2015 Nov 17.
4
Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR.硼替佐米联合地塞米松方案中添加达雷妥尤单抗治疗复发/难治性多发性骨髓瘤的经济学评价：基于 CASTOR 最新更新分析。
Clin Ther. 2020 Feb;42(2):251-262.e5. doi: 10.1016/j.clinthera.2019.12.007. Epub 2020 Jan 20.
5
Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone.在接受卡非佐米或泊马度胺单药或联合地塞米松治疗的复发或难治性多发性骨髓瘤患者中，医疗保健的利用和费用。
J Med Econ. 2019 Aug;22(8):818-829. doi: 10.1080/13696998.2019.1614932. Epub 2019 May 17.
6
Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.达雷妥尤单抗单药治疗与泊马度胺联合低剂量地塞米松治疗多发性骨髓瘤的疗效比较：匹配调整间接比较。
Oncologist. 2018 Mar;23(3):279-287. doi: 10.1634/theoncologist.2017-0103. Epub 2017 Nov 30.
7
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.从美国视角看，在复发多发性骨髓瘤中，将卡非佐米添加至来那度胺和地塞米松方案的成本效益分析
J Med Econ. 2016 Nov;19(11):1061-1074. doi: 10.1080/13696998.2016.1194278. Epub 2016 Jun 16.
8
Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4.接受 cilta-cabtagene autoleucel 治疗的 lenalidomide 难治性多发性骨髓瘤患者的成本-反应者分析。在 CARTITUDE-4 研究中。
Front Immunol. 2024 Aug 21;15:1408892. doi: 10.3389/fimmu.2024.1408892. eCollection 2024.
9
Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma.达雷妥尤单抗、泊马度胺和地塞米松联合疗法治疗对达雷妥尤单抗和/或泊马度胺难治的多发性骨髓瘤
Br J Haematol. 2019 Jul;186(1):140-144. doi: 10.1111/bjh.15716. Epub 2018 Dec 11.
10
Cost-Effectiveness of Novel Agent Regimens for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients in India.新型药物方案治疗印度适合移植的新诊断多发性骨髓瘤患者的成本效益分析。
Appl Health Econ Health Policy. 2024 Jul;22(4):569-582. doi: 10.1007/s40258-024-00877-1. Epub 2024 Mar 7.

引用本文的文献

1
Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.在复发或难治性多发性骨髓瘤患者中，将达雷妥尤单抗添加至卡非佐米和地塞米松方案的经济学评估
Risk Manag Healthc Policy. 2024 Nov 16;17:2829-2837. doi: 10.2147/RMHP.S475048. eCollection 2024.
2
Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma.达雷妥尤单抗作为一线治疗药物，在适合移植的新诊断多发性骨髓瘤患者中具有成本效益。
Blood. 2022 Aug 11;140(6):594-607. doi: 10.1182/blood.2021015220.
3
A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma.
新型药物治疗多发性骨髓瘤的成本效益分析系统评价
Cancers (Basel). 2021 Nov 9;13(22):5606. doi: 10.3390/cancers13225606.
4
Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.基于 III 期 BOSTON 试验结果，三药联合塞利昔布-硼替佐米-地塞米松（XVd）在既往治疗多发性骨髓瘤（MM）中的成本效益。
Pharmacoeconomics. 2021 Nov;39(11):1309-1325. doi: 10.1007/s40273-021-01068-9. Epub 2021 Aug 9.
5
Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma.硼替佐米、美法仑和泼尼松联合达雷妥尤单抗治疗新诊断多发性骨髓瘤的成本效果分析。
Adv Ther. 2021 May;38(5):2379-2390. doi: 10.1007/s12325-021-01699-6. Epub 2021 Mar 26.
6
Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma.在未经治疗的多发性骨髓瘤中，将达雷妥尤单抗添加至硼替佐米、美法仑和泼尼松方案的成本效益分析
Front Pharmacol. 2021 Mar 1;12:608685. doi: 10.3389/fphar.2021.608685. eCollection 2021.
7
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).泊马度胺、环磷酰胺和地塞米松治疗复发/难治性老年多发性骨髓瘤患者：韩国多发性骨髓瘤工作组（KMMWP-164 研究）。
Am J Hematol. 2020 Apr;95(4):413-421. doi: 10.1002/ajh.25726. Epub 2020 Jan 24.